Healio

FDA approves Actemra subcutaneous injection for active systemic JIA

The FDA has approved the subcutaneous formulation of tocilizumab for the treatment of active systemic juvenile idiopathic arthritis in patients aged 2 years and older, according to a press release ...
Monthly Prescribing Reference

Actemra Gains New Indication for Systemic Sclerosis-Associated Interstitial Lung Disease

The FDA has approved Actemra® (tocilizumab; Genentech) subcutaneous injection for slowing the rate of decline in pulmonary function in SSc-ILD. The Food and Drug Administration (FDA) has approved ...
Monthly Prescribing Reference

Actemra SC Approved to Treat Rare Form of Juvenile Arthritis

The efficacy of Actemra SC among pediatric patients (ages 2–17) was extrapolated from established data of Actemra IV in PJIA patients and of Actemra SC in patients with rheumatoid arthritis. For SC ...
Reuters

Roche: Actemra injection as good as infusion

ZURICH, July 19 (Reuters) - Roche's Japanese subsidiary Chugai said on Tuesday subcutaneous injection of its Actemra drug has shown efficacy in rheumatoid arthritis compared to intravenous infusion.
Business Wire

FDA Approves Subcutaneous Formulation of Actemra for Use in Active Systemic Juvenile Idiopathic Arthritis (SJIA), a Rare Form of Juvenile Arthritis

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved the ...
FiercePharma

Genentech Reports Second Positive Study of ACTEMRA® Given by Subcutaneous Injection to Patients with Rheumatoid Arthritis

GenentechMedia:Joe St. Martin, 650-467-6800orInvestor:Thomas Kudsk Larsen, 650-467-2016Karl Mahler, 011 41 61 687 85 03 Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today ...
FiercePharma

Actemra®, a Treatment for Rheumatoid Arthritis Obtained Approval for Subcutaneous Injection Formulation

March 25, 2013 (Tokyo) - Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku Tokyo; Chairman & CEO: Osamu Nagayama (hereafter, "Chugai")] announced today that the subcutaneous injection formulation ...
EurekAlert!

Phase 3 trial confirms superiority of tocilizumab to steroids for giant cell arteritis

A phase 3 clinical trial has confirmed that regular treatment with tocilizumab, an inhibitor of interleukin-6, successfully reduced both symptoms of and the need for high-dose steroid treatment for ...
Business Wire

FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Actemra ...
Seeking Alpha

Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.

Strengthens and expands U.S. biosimilars immunology portfolio with multi-indication arthritis treatment “Biosimilars continue to be a key growth driver for Organon, and this acquisition complements ...
Healio

FDA approves Actemra subcutaneous injection for polyarticular JIA

Please provide your email address to receive an email when new articles are posted on . The FDA has approved the subcutaneous formulation of Actemra for the treatment of polyarticular juvenile ...